Omeros Corporation Stock News

Seattle biotech company Omeros Corp. is seeking accelerated approval from the Federal Drug Administration for its drug that aims to fight a life-threatening disorder that can develop after receiving a

BidaskClub upgraded shares of Omeros (NASDAQ:OMER) from a strong sell rating to a sell rating in a research note released on Friday, BidAskClub reports. A number of other equities analysts have also w

So far Monday, January 20, NASDAQ is down -3.65% and the S&P is up 0.25%. Let’s take a look at

So far Sunday, January 19, NASDAQ is down -3.65% and the S&P is up 0.25%. Let’s take a look at

So far Saturday, January 18, NASDAQ is down -3.65% and the S&P is up 0.25%. Here are this morning’s most

A look at the shareholders of Omeros Corporation (NASDAQ:OMER) can tell us which group is most powerful. Institutions...

Equities research analysts forecast that Omeros Co. (NASDAQ:OMER) will report sales of $31.38 million for the current fiscal quarter, Zacks Investment Research reports. Two analysts have issued estima

DUBLIN--(BUSINESS WIRE)--The "Glomerulonephritis - Pipeline Review, H2 2019" drug pipelines has been added to ResearchAndMarkets.com's offering. Glomerulonephritis is also known as glomerular nephriti

Last year's fourth quarter was a rough one for investors and many hedge funds, which were naturally unable to overcome the big dip in the broad market, as the S&P; 500 fell by about 4.8% during 2018 a

AMSTERDAM & SEATTLE--(BUSINESS WIRE)--myTomorrows, a global health technology company, and Omeros Corporation (Nasdaq: OMER), an innovative biopharmaceutical company committed to discovering, developi

SEATTLE--(BUSINESS WIRE)--Omeros Corporation (Nasdaq: OMER) last week presented new data directed to its novel cancer immunotherapy target GPR174 at the European Society for Medical Oncology (ESMO) 20

SEATTLE--(BUSINESS WIRE)--Omeros Corporation (Nasdaq: OMER) (“Omeros”), a commercial-stage biopharmaceutical company committed to discovering, developing and commercializing small-molecule and pro

SEATTLE--(BUSINESS WIRE)--Omeros Corporation (Nasdaq: OMER) today announced an upcoming presentation directed to its novel cancer immunotherapy target GPR174 at the European Society for Medical Oncolo